

## CardioMetabolic Diseases

Our innovation in CardioMetabolic diseases is evidenced through our long history of excellence in research and landmark clinical trials, culminating in our most recent breakthrough treatments in type 2 diabetes and anticoagulation care. We are also committed to discovering and developing the innovations of the future and are searching for differentiated novel products and new therapeutic concepts (compound-related research targets or new pathways/ideas), with a preference for discovery up to IND-ready programs.

Our specific partnering interests offer various opportunities for collaboration with a focus on therapies that address microvascular and macrovascular complications of diabetes and the metabolic syndrome.

### Liver diseases

- Non-alcoholic steatohepatitis (NASH), liver fibrosis, cirrhosis

### Diabetic retinopathy (DME, PDR, nPDR)

### Chronic kidney diseases

- Chronic kidney disease, and approaches targeting pathophysiologies in the cardio-renal axis, including heart failure, acute kidney injury, renal inflammation and fibrosis

### Novel obesity treatments achieving weight loss > 10%

### Breakthrough treatments for type 2 diabetes, Pancreas recovery options

**If you share our goal of researching and developing new medications to improve the health of people around the world please join us in...**

**Working together  
for better health**

For more information please contact our BD&L team:

Dr. Johannes Zanzinger

[johannes.zanzinger@boehringer-ingelheim.com](mailto:johannes.zanzinger@boehringer-ingelheim.com)

Dr. Monica Cheng

[monica.cheng@boehringer-ingelheim.com](mailto:monica.cheng@boehringer-ingelheim.com)

Dr. Manuel Baader

[manuel.baader@boehringer-ingelheim.com](mailto:manuel.baader@boehringer-ingelheim.com)

